HomeMarket NewsThe Best Health Stock Gems to Snatch Up Amid Turbulence

The Best Health Stock Gems to Snatch Up Amid Turbulence

Actionable Trade Ideas

always free


Opportunities in vTv Therapeutics (VTVT)

vTv Therapeutics (NASDAQ:VTVT) stands at a crossroads as it inches closer to launching its Phase 3 trial of TTP399, a drug candidate showing remarkable potential in reducing hypoglycemic episodes in Type 1 diabetes patients. Despite previous hurdles, a recent $51 million private placement signals a turning point for the company, paving the way for the long-awaited trial to kick off this year. Backed by notable investors like Samsara BioCapital and the JDRF T1D Fund, vTv is poised for a resurgence, making it a prime contender for investors seeking growth in the healthcare sector. Even with its recent rollercoaster ride in the stock market, the bright prospects of vTv’s flagship drug make it a compelling choice for savvy investors.

Exact Sciences (EXAS) – A Beacon of Resilience

Amidst the tumultuous market conditions, Exact Sciences (NASDAQ:EXAS) shines as a beacon of resilience in the healthcare landscape. The firm’s robust performance in the fourth quarter, with a 17% year-over-year surge in revenue to $647 million, underscores its unwavering commitment to innovation and growth. Notably, Exact Sciences is diversifying its revenue streams beyond its flagship Cologuard colon cancer test, with promising results from its Oncoptype tests driving overseas revenue up by 48%. With strategic plans to expand into new markets and introduce novel tests like MRD and OncoLiquid, Exact Sciences is positioned for substantial revenue growth. Despite recent market dips, Exact Sciences’ steadfast focus on enhancing its product portfolio keeps it in good stead for future success in the healthcare sector.

Excientia (EXAI) – Navigating Stormy Seas with AI Innovation

The turbulent waters facing Exscientia (NASDAQ:EXAI) have not dampened the spirit of this pioneering company, which leverages AI to expedite drug discovery processes. Bolstered by partnerships with major pharmaceutical players, Exscientia’s cutting-edge technology is poised to revolutionize the industry. The recent shakeup in leadership, with the removal of CEO Andrew Hopkins, has paved the way for new leadership under Chief Science Officer Dave Hallett. Despite initial market jitters post-management changes, Exscientia’s innovative approach to drug research holds promise for sustained growth and advancement. While recent market fluctuations have impacted EXAI stock, the company’s AI-driven strategy remains a beacon of hope in the healthcare sector.

On the date of publication, Larry Ramer held long positions in VTVT and EXAS. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comΒ Publishing Guidelines.

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.